



(51) International Patent Classification:

A61K 31/7115 (2006.01) C12N 15/113 (2010.01)
A61P 13/12 (2006.01)

(21) International Application Number:

PCT/US2024/024006

(22) International Filing Date:

11 April 2024 (11.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/495,576 12 April 2023 (12.04.2023) US
63/563,881 11 March 2024 (11.03.2024) US

(71) Applicant: **REGULUS THERAPEUTICS INC.**

[US/US]; 4224 Campus Point Court, Suite 210, San Diego,
California 92121 (US).

(72) Inventors: **LEE, Edmund Chun Yu**; c/o Regulus Ther-

apeutics Inc., 4224 Campus Point Court, Suite 210, San
Diego, California 92121 (US). **GARG, Rekha**; c/o Regulus
Therapeutics Inc., 4224 Campus Point Court, Suite 210, San
Diego, California 92121 (US).

(74) Agent: **SCARR, Rebecca** et al.; McNeill Baur PLLC, 125
Cambridge Park Drive, Suite 301, Cambridge, Massachu-
setts 02140 (US).


(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.


(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,


(54) Title: MODIFIED OLIGONUCLEOTIDE FOR TREATING POLYCYSTIC KIDNEY DISEASE




Guanosine
G




Inosine
I




2-Aminopurine
AP



2,6-Diaminopurine
DAP



IsoGuanosine
IsoG



Adenosine
A

Purine numbering




FIG. 1

(57) Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

[Continued on next page]



SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*